IT20.F Aclarion, Inc.
- Market cap
- EUR 3.43M
- P/E
- -
- P/B
- 0.25x
- ROE
- -74.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IT20.F undervalued?
Graham numberThe Graham number of Aclarion, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aclarion, Inc. fundamental analysis
No fundamental analysis for Aclarion, Inc. yet.
Aclarion, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aclarion, Inc.
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequen…
Full company profileAclarion, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aclarion, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 60.3K | 60.4K | 75.4K | 45.7K | 75.7K | 107K |
| Gross Profit | -8.88K | -4.85K | -324.00 | -38.9K | 6.83K | 35.8K |
| Operating Income | -2.95M | -5.56M | -4.88M | -5.51M | -7.05M | -11.5M |
| EBITDA | - | -5.42M | -4.14M | -6.26M | -7.01M | -11.3M |
| Net Income | -4.95M | -7.07M | -4.91M | -6.99M | -7.23M | -11.0M |
| EPS | -101,026 | -130,900 | -53,971 | -5,108 | -8.47 | -3.80 |
| Balance Sheet | ||||||
| Total Assets | 1.89M | 2.91M | 2.46M | 2.12M | 13.7M | 15.8M |
| Total Liabilities | 7.62M | 689K | 3.19M | 1.15M | 837K | 1.03M |
| Shareholders' Equity | -5.73M | 2.23M | -728K | 970K | 12.8M | 14.8M |
| Cash & Short-term Investments | 433K | 1.47M | 1.02M | 454K | 12.0M | 14.2M |
| Cash Flow | ||||||
| Operating Cash Flow | -2.40M | -4.95M | -3.65M | -5.27M | -7.16M | -9.76M |
| Capital Expenditure | 102K | 209K | 120K | 322K | 204K | 220K |
| Free Cash Flow | -2.50M | -5.16M | -3.77M | -5.59M | -7.37M | -9.98M |
| Ratios | ||||||
| ROE | - | -317.6% | - | -720.9% | -56.4% | -74.1% |
| ROA | -262.0% | -242.5% | -199.7% | -329.3% | -52.9% | -69.2% |
| Net Profit Margin | -8,210.5% | -11,694.4% | -6,513.4% | -15,293.8% | -9,551.9% | -10,268.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Aclarion, Inc. dividends
Aclarion, Inc. has not paid dividends in the last 5 fiscal years.
Who owns Aclarion, Inc.
- Insiders 23.98%
- Institutions 3.96%
- Public & others 72.07%
- Shares outstanding 2.88M
- Free float 2.52M
Aclarion, Inc. company profile
- Company name
- Aclarion, Inc.
- Ticker
- IT20.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Information Services
- Employees
- 10
- Fiscal year end
- December
- Address
- 8181 Arista Place, Broomfield, CO, United States, 80021
- Phone
- 833 275 2266
- Website
- aclarion.com
About Aclarion, Inc.
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Aclarion, Inc. management
4- Dr. Jeffrey John Thramann M.D.Executive Chairman · born 1965
- Mr. Brent NessCEO, President & Director · born 1967
- Mr. Gregory A. Gould CPAChief Financial Officer · born 1966
- Mr. Ryan BondChief Strategy Officer · born 1972